Vanguard Capital Management
UTHR icon

Vanguard Capital Management’s United Therapeutics UTHR Stock Holding History

Vanguard Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04B Sell
1,918,256
-39,283
-2% -$22.1M 0.02% 493
2026
Q1 		$1.16B Buy
+1,957,539
New +$975M 0.03% 440

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management's UTHR Position: Q2 2026 in Review

Vanguard Capital Management reduced its United Therapeutics (UTHR) stake by 2% in Q2 2026, selling an estimated $22.1M and leaving 1,918,256 shares worth $1.04B. The position accounts for 0.02% of the portfolio, ranked #493.

Vanguard Capital Management first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.16B in Q1 2026. 818 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Vanguard Capital Management held 1,918,256 shares of United Therapeutics worth $1.04B as of Q2 2026.
  • Vanguard Capital Management sold 39,283 United Therapeutics shares in Q2 2026, an estimated $22.1M.
  • United Therapeutics made up 0.02% of Vanguard Capital Management's portfolio in Q2 2026, its #493 holding.
  • Vanguard Capital Management first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's United Therapeutics position peaked at $1.16B in Q1 2026.
  • 818 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.